The EFCAB14 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma epithelial cell line. This product features CRISPR/Cas9-mediated gene disruption of the EFCAB14 locus, yielding a heterogeneous pool of edited cells. The polyclonal format provides a versatile loss-of-function model for studying EFCAB14 function without single-cell clonal isolation, enabling robust analysis of gene disruption effects in a cancer-relevant background.
The A2780 host cell line is a well-established human ovarian cancer model isolated from an untreated patient. These epithelial cells retain key characteristics of ovarian carcinoma, including rapid proliferation and sensitivity to platinum-based agents such as cisplatin. A2780 cells are widely used to investigate tumorigenic signaling, drug resistance mechanisms, and cell cycle regulation, making them an appropriate system for exploring the tumor-associated roles of EFCAB14.
EFCAB14 encodes an EF-hand calcium-binding protein that likely functions as a sensor of intracellular calcium fluctuations. It is regulated by intracellular calcium levels and calcium-dependent kinases, and interacts with calmodulin as well as centrosomal and ciliary proteins. Within its signaling network, EFCAB14 operates alongside calcium ions, calmodulin, and microtubules, and its activity is predicted to influence downstream calcium-sensitive effectors and cell cycle proteins. Thus, EFCAB14 may serve as a molecular link between calcium signaling and centrosomal or ciliary functions.
Disrupting EFCAB14 in A2780 ovarian cancer cells offers a powerful system to examine its contribution to calcium-mediated pathways and cell cycle control. Because aberrant calcium signaling and centrosomal dysregulation are associated with ovarian cancer progression, this knockout model can reveal how EFCAB14 loss impacts proliferation, apoptosis, or microtubule organization. Such insights may clarify the protein??s role in tumor cell biology and its potential as a therapeutic vulnerability.
This polyclonal knockout pool supports a range of functional assays. Knockout confirmation can be performed by Western blotting and RT-qPCR. Downstream applications include calcium imaging to monitor calcium dynamics, flow cytometry for cell cycle analysis, apoptosis assays, and migration/invasion studies. Drug sensitivity testing, such as cisplatin response profiling, can assess EFCAB14??s influence on chemoresistance. These tools make the EFCAB14 Knockout A2780 Polyclonal Cells ideal for ovarian cancer research, calcium signaling investigations, and cell cycle studies. For additional technical support, please contact Ascent Research.
